Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
| Autor: | Steven J. Greenberg, Ping Wang, Glenn Phillips, Heinz Wiendl, Gavin Giovannoni, Stanley Cohan, Krzysztof Selmaj, Wei Ma, Ludwig Kappos, Guido Sabatella, John W. Rose, Gabriel Paiva da Silva Lima, Eva Havrdova |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty interferon beta-1a Daclizumab Multiple Sclerosis Patient demographics efficacy Subgroup analysis Daclizumab beta Antibodies Monoclonal Humanized relapsing-remitting multiple sclerosis Disease activity 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Disability progression 030212 general & internal medicine subgroup analysis business.industry Multiple sclerosis Interferon beta-1a Middle Aged medicine.disease disability progression Treatment Outcome Neurology Immunoglobulin G Immunology Disease Progression Female Neurology (clinical) business Original Research Papers Immunosuppressive Agents 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis (Houndmills, Basingstoke, England) |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/1352458517735190 |
| Popis: | Background: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. Objective: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE. Methods: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29 PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined by baseline demographic/disease characteristics. Results: Daclizumab beta significantly reduced risk of 24-week CDP (hazard ratio (HR), 0.73; 95% confidence interval (95% CI), 0.55–0.98), risk of 24-week sustained MSFCS progression (HR, 0.80; 95% CI, 0.67–0.95), and odds of clinically meaningful worsening in MSIS-29 PHYS (odds ratio, 0.76; 95% CI, 0.60–0.95) versus IM interferon beta-1a. Point estimates showed trends favoring daclizumab beta over IM interferon beta-1a across several patient subgroups for all three outcome measures. Conclusion: Daclizumab beta showed consistent benefit versus IM interferon beta-1a across measures assessing patient disability/function and across a range of clinical baseline characteristics in patients with relapsing-remitting MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|